Compare Stocks: BIIB, ATAI, IXHL, NRXP, and ENVB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Beckley	$7.18	$5.20	$3.27 ▼ $7.22	$2.64B	1.54	20.79 million shs	8.91 million shs
BIIB Biogen	$202.95	$201.23	$124.56 ▼ $219.72	$29.99B	0.17	1.47 million shs	1.06 million shs
ENVB Enveric Biosciences	$1.57	$1.55	$1.25 ▼ $17.64	$5.78M	1.15	111,233 shs	77,502 shs
IXHL Incannex Healthcare	$2.94	$3.38	$2.49 ▼ $27.69	$35.19M	6.98	161,536 shs	71,232 shs
NRXP NRx Pharmaceuticals	$3.15	$3.99	$1.62 ▼ $5.05	$114.12M	2.18	883,299 shs	1.14 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Beckley	0.00%	0.00%	+38.34%	+73.43%	+72.18%
BIIB Biogen	0.00%	+0.38%	-6.09%	+8.49%	+53.81%
ENVB Enveric Biosciences	0.00%	+21.71%	+8.28%	-60.65%	-88.62%
IXHL Incannex Healthcare	0.00%	-0.34%	-25.94%	-35.38%	-74.58%
NRXP NRx Pharmaceuticals	0.00%	-16.00%	-18.60%	+1.94%	+21.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Beckley	$7.18	$5.20	$3.27 ▼ $7.22	$2.64B	1.54	20.79 million shs	8.91 million shs
BIIB Biogen	$202.95	$201.23	$124.56 ▼ $219.72	$29.99B	0.17	1.47 million shs	1.06 million shs
ENVB Enveric Biosciences	$1.57	$1.55	$1.25 ▼ $17.64	$5.78M	1.15	111,233 shs	77,502 shs
IXHL Incannex Healthcare	$2.94	$3.38	$2.49 ▼ $27.69	$35.19M	6.98	161,536 shs	71,232 shs
NRXP NRx Pharmaceuticals	$3.15	$3.99	$1.62 ▼ $5.05	$114.12M	2.18	883,299 shs	1.14 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Beckley	0.00%	0.00%	+38.34%	+73.43%	+72.18%
BIIB Biogen	0.00%	+0.38%	-6.09%	+8.49%	+53.81%
ENVB Enveric Biosciences	0.00%	+21.71%	+8.28%	-60.65%	-88.62%
IXHL Incannex Healthcare	0.00%	-0.34%	-25.94%	-35.38%	-74.58%
NRXP NRx Pharmaceuticals	0.00%	-16.00%	-18.60%	+1.94%	+21.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Beckley	2.27	Hold	$11.06	53.99% Upside
BIIB Biogen	2.56	Moderate Buy	$223.36	10.06% Upside
ENVB Enveric Biosciences	1.00	Sell	N/A	N/A
IXHL Incannex Healthcare	2.00	Hold	$18.00	512.24% Upside
NRXP NRx Pharmaceuticals	2.50	Moderate Buy	$38.25	1,114.29% Upside

Current Analyst Ratings Breakdown

Latest BIIB, ATAI, IXHL, NRXP, and ENVB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	BIIB Biogen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$237.00 ➝ $251.00
7/30/2026	BIIB Biogen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$242.00 ➝ $240.00
7/30/2026	BIIB Biogen	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$225.00 ➝ $240.00
7/30/2026	BIIB Biogen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$245.00 ➝ $248.00
7/30/2026	BIIB Biogen	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$222.00 ➝ $231.00
7/30/2026	BIIB Biogen	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$215.00 ➝ $225.00
7/30/2026	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$201.00 ➝ $215.00
7/29/2026	BIIB Biogen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
7/29/2026	BIIB Biogen	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$300.00
7/29/2026	BIIB Biogen	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$185.00 ➝ $200.00
7/20/2026	ATAI Atai Beckley	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.45

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Beckley	$4.09M	646.32	N/A	N/A	$0.69 per share	10.41
BIIB Biogen	$9.89B	3.03	$22.63 per share	8.97	$124.45 per share	1.63
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	$7.00 per share	N/A
IXHL Incannex Healthcare	$90K	391.02	N/A	N/A	$2.07 per share	1.42
NRXP NRx Pharmaceuticals	$1.23M	92.78	N/A	N/A	($0.54) per share	-5.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Beckley	-$660.05M	-$2.23	N/A	N/A	N/A	-19,019.44%	-89.79%	-63.58%	8/13/2026 (Estimated)
BIIB Biogen	$1.29B	$5.65	35.92	12.31	6.20	8.32%	11.18%	6.88%	N/A
ENVB Enveric Biosciences	-$8.77M	-$23.54	N/A	N/A	N/A	N/A	-220.97%	-177.47%	8/17/2026 (Estimated)
IXHL Incannex Healthcare	-$46.88M	-$1.55	N/A	N/A	N/A	N/A	-81.01%	-76.11%	9/2/2026 (Estimated)
NRXP NRx Pharmaceuticals	-$28.62M	-$1.09	N/A	5.34	N/A	N/A	N/A	-202.92%	8/17/2026 (Estimated)

Latest BIIB, ATAI, IXHL, NRXP, and ENVB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/17/2026	Q2 2026	NRXP NRx Pharmaceuticals	-$0.09	N/A	N/A	N/A	$1.75 million	N/A
8/13/2026	Q2 2026	ATAI Atai Beckley	-$0.1088	N/A	N/A	N/A	$0.11 million	N/A
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion
5/15/2026	Q1 2026	ENVB Enveric Biosciences	N/A	-$1.08	N/A	-$1.08	N/A	N/A
5/15/2026	Q1 2026	NRXP NRx Pharmaceuticals	-$0.05	-$0.04	+$0.01	-$0.04	$19.43 million	$1.07 million
5/12/2026	Q4 2025	ATAI Atai Beckley	-$0.11	-$0.08	+$0.03	-$0.08	$0.22 million	$0.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Beckley	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
ENVB Enveric Biosciences	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Beckley	N/A	N/A	N/A
BIIB Biogen	0.39	1.87	1.26
ENVB Enveric Biosciences	N/A	11.66	11.66
IXHL Incannex Healthcare	N/A	41.56	41.56
NRXP NRx Pharmaceuticals	N/A	0.29	0.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Beckley	28.41%
BIIB Biogen	87.93%
ENVB Enveric Biosciences	13.82%
IXHL Incannex Healthcare	0.43%
NRXP NRx Pharmaceuticals	4.27%

Insider Ownership

Company	Insider Ownership
ATAI Atai Beckley	19.80%
BIIB Biogen	0.25%
ENVB Enveric Biosciences	2.41%
IXHL Incannex Healthcare	1.33%
NRXP NRx Pharmaceuticals	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Beckley	80	368.17 million	295.27 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
ENVB Enveric Biosciences	20	3.68 million	3.59 million	Not Optionable
IXHL Incannex Healthcare	3	11.97 million	11.81 million	Not Optionable
NRXP NRx Pharmaceuticals	2	36.23 million	33.91 million	Optionable

BIIB, ATAI, IXHL, NRXP, and ENVB Headlines

Recent News About These Companies

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

July 21, 2026 | marketbeat.com

NRx Pharmaceuticals (NASDAQ:NRXP) Shares Up 0.7% - Time to Buy?

July 17, 2026 | marketbeat.com

Is NRx Pharmaceuticals, Inc. (NRXP) Stock Positioned for Growth Through Depression and PTSD Treatment Innovation?

July 15, 2026 | insidermonkey.com

NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute

June 25, 2026 | globenewswire.com

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

June 25, 2026 | globenewswire.com

Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition

June 24, 2026 | businesswire.com

ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics

June 23, 2026 | prnewswire.com

NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the ...

June 22, 2026 | markets.businessinsider.com

NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

June 22, 2026 | globenewswire.com

NRX Pharmaceuticals Inc (NRXP) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...

June 18, 2026 | finance.yahoo.com

NRx Pharmaceuticals (NRXP) Closes Underwritten Public Offering of Common Stock At $3.50 Per Share

June 10, 2026 | insidermonkey.com

NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

June 5, 2026 | globenewswire.com

NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option

June 5, 2026 | markets.businessinsider.com

NRx Pharmaceuticals Announces $20 Million Public Stock Offering

June 4, 2026 | tipranks.com

NRx Pharmaceuticals Closes $22.3 Million Public Offering to Support Growth and Development of CNS Therapeutics

June 4, 2026 | quiverquant.comQ

NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' Option

June 4, 2026 | globenewswire.com

NRx Pharmaceuticals Plans Underwritten Public Stock Offering

June 4, 2026 | theglobeandmail.com

NRx Pharmaceuticals Prices Public Offering of Common Stock to Raise Approximately $20 Million

June 3, 2026 | quiverquant.comQ

NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

June 3, 2026 | globenewswire.com

NRx Pharmaceuticals (NRXP) stock fell 19% after hours on Tuesday: Here's why

June 3, 2026 | msn.com

NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

June 2, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB, ATAI, IXHL, NRXP, and ENVB Company Descriptions

Atai Beckley NASDAQ:ATAI

$7.18 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$7.18 0.00 (-0.01%)

As of 07/31/2026 08:00 PM Eastern

Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Biogen NASDAQ:BIIB

$202.95 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$204.62 +1.68 (+0.83%)

As of 07/31/2026 07:34 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Enveric Biosciences NASDAQ:ENVB

$1.57 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$1.52 -0.05 (-3.18%)

As of 07/31/2026 07:44 PM Eastern

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Incannex Healthcare NASDAQ:IXHL

$2.94 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$2.90 -0.04 (-1.36%)

As of 07/31/2026 07:52 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

NRx Pharmaceuticals NASDAQ:NRXP

$3.15 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$3.24 +0.10 (+3.02%)

As of 07/31/2026 07:59 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BIIB, ATAI, IXHL, NRXP, and ENVB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BIIB, ATAI, IXHL, NRXP, and ENVB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BIIB, ATAI, IXHL, NRXP, and ENVB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB, ATAI, IXHL, NRXP, and ENVB Company Descriptions

Atai Beckley NASDAQ:ATAI

Biogen NASDAQ:BIIB

Enveric Biosciences NASDAQ:ENVB

Incannex Healthcare NASDAQ:IXHL

NRx Pharmaceuticals NASDAQ:NRXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BIIB, ATAI, IXHL, NRXP, and ENVB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BIIB, ATAI, IXHL, NRXP, and ENVB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BIIB, ATAI, IXHL, NRXP, and ENVB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB, ATAI, IXHL, NRXP, and ENVB Company Descriptions

Atai Beckley NASDAQ:ATAI

Biogen NASDAQ:BIIB

Enveric Biosciences NASDAQ:ENVB

Incannex Healthcare NASDAQ:IXHL

NRx Pharmaceuticals NASDAQ:NRXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools